)
Edge23 Jan 2026
Death, Taxes, and Garbage: The Story of WM
How Waste Management turned garbage into one of America's most stable business models through landfills, regulation, and nationwide scale.
Apogee Therapeutics
Apogee Therapeutics (APGE) investor relations material
Apogee Therapeutics Study Result summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Study Result summary6 Jan, 2026
Key study objectives and design
Phase 1b trial aimed to confirm safety and demonstrate activity of zumilokibart in asthma patients, focusing on FeNO reduction as a surrogate marker for Type 2 inflammation.
Double-blind, placebo-controlled, single-dose regimen with 19 patients (3:1 active:placebo) meeting pre-specified criteria.
Primary objectives included safety, maximum mean FeNO reduction, and sustained FeNO suppression to support infrequent dosing.
Interim results and efficacy
Interim phase 1b results showed robust, rapid, and durable FeNO suppression, with a 60% reduction (45 ppb) sustained for at least 16 weeks after a single 720 mg dose, and up to 32 weeks in some patients.
FeNO suppression was competitive with or exceeded standard-of-care biologics, including DUPIXENT and TEZSPIRE, which require more frequent dosing.
Positive trends were observed in FEV1 and Type 2 inflammatory biomarkers, with further data to be presented at upcoming conferences.
The study population was enriched for Type 2 inflammation, with most patients having eosinophil counts ≥150, aligning with future trial plans.
Safety and tolerability
The safety profile was favorable, with no serious or drug-related adverse events, no Grade 3/4 TEAEs, and no anti-drug antibodies detected.
Only mild, grade 1 gastroesophageal reflux (GERD) was reported in more than one patient; no cases of conjunctivitis or injection site reactions.
Safety profile consistent with other IL-13 targeting therapies in asthma.
Demographics and baseline characteristics were well-balanced between treatment and placebo groups.
Confirm best-in-class dosing profile for APG777
APG777 asthma: Next steps for market expansion
APG279 vs. DUPIXENT: Key differentiation points
Compare zumi's FeNO durability to IL-4RA agents
How does dual label impact payer access and pricing?
What is the efficacy bar for non-T2 asthma combos?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Apogee Therapeutics earnings date
Q4 20254 Mar, 2026
Apogee Therapeutics
Next Apogee Therapeutics earnings date
Q4 20254 Mar, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Apogee Therapeutics Inc. (APGE) is a biotechnology company engaged in the development of differentiated biologics for the treatment of various inflammatory and immunology (I&I) diseases, including atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and other conditions with high unmet medical needs. The company's approach is focused on creating best-in-class therapies that aim to improve upon the current standard of care for these conditions. The company is headquartered in San Francisco, California, and Waltham, Massachusetts, and its shares are listed on the Nasdaq.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage